materials; well under 10% of total housekeeping costs are for the products used for cleaning and/or disinfecting floors.
Detection of Bacteremia: Technical Aspects of the Blood Culture
To the Editor:
In the article "Detection of Bacteremia: Technical aspects of the blood culture" (2:399-400, 1981), I would like to respectfully disagree with Dr. Weinstein's statement on subcultures. He comments that subcultures are routine at 7 or 14 days before the blood culture is discarded. While this practice may currently be the case in many hospitals, this practice should now be abandoned. In the past two years, several studies have been done which indicate that the terminal subculture does not detect previously unsuspected bacteremia. Those terminal subcultures that are positive usually appear from patients where other blood cultures were positive earlier. These studies have been documented in standard blood culture media involving over 14,000 blood cultures in a study by Campbell 1 " 3 One study reported observations made during a three-week study period 1 and another examined results during a three-month time span. 3 These somewhat limited evaluations may not be adequate to support Dr. Gross' conclusion that the practice of performing terminal subcultures be abandoned completely. Indeed, Araj et al 3 concluded their report by recommending that laboratories review their terminal subculture results before making changes in blood culture policy. In at least one institution where this recommendation was followed, the microbiologist decided to continue performing terminal subcultures.
Campbell and Washington suggest that seven days incubation of blood cultures is probably adequate for general hospitals but that a second week of incubation is indicated in suspected endocarditis, persistent or recurrent infection, and in laboratories which serve referral centers. ' Reller also has recommended a two-week incubation of blood cultures in suspected endocarditis. 5 To my knowledge there are no published data on the value of terminal subcultures at the end of a two-week incubation period. During a 21-month period (1975) (1976) (1977) at the University of Colorado Health Sciences Center (UCHSC), more than 15,000 blood cultures were obtained of which 1069 (7%) were positive for microorganisms which represented true bacteremia as determined clinically by members of the Infectious Disease Service (Weinstein MP, Reller LB, unpublished data). Fifty-three microorganisms, representing 5% of all clinically important isolates, were detected only by the terminal subculture at 14 days. Since 1977 the clinical microbiology laboratory at UCHSC has continued to identify 5% of clinically important isolates, in particular gonococci, cryptococci, and Candida spp., only by the terminal subculture (Reller LB, personal communication) . While the yield is limited, the accompanying table shows that the microorganisms isolated represent a broad spectrum of human pathogens.
Is the limited yield worth the extra cost and effort? Laboratory directors hopefully in consultation with interested clinicians, will have to judge the relative value of terminal subcultures in their institutions. At our teaching hospital all blood cultures are incubated for 14 days, and terminal subcultures are and will continue to be performed.
Lastly, Dr. Gross' letter confuses data from two of the studies he quotes. Campbell It is desirable to perform liver function tests, such as SGGT, alkaline-phosphatase, SGPT, SGOT and bilirubin, before treatment and at periodic intervals during treatment (monthly or more frequent), particularly in patients who will be on prolonged therapy or who have a history of liver disease, instances of minor elevations of liver enzyme levels in patients on NIZORAL* have been shown to normalize during therapy and may not necessitate discontinuation of treatment. However, if liver function tests are significantly elevated or other signs and symptoms are suggestive of hepatocellular dysfunction, ketoconazole should be discontinued. In female rats treated three to six months with ketoconazole at dose levels of 80 mg/kg and higher, increased fragility of long bones, in some cases leading to fracture, was seen. The maximum "no-effect" dose level In these studies was 20 mg/kg (2.5 times the maximum recommended human dose). The mechanism responsible for this phenomenon is obscure. Limited studies in dogs failed to demonstrate such an effect on the metacarpals and ribs. PRECAUTIONS Baiwril. In four subjects with drug-induced achlorhydria, a marked reduction in NIZORAL* absorption was observed. NIZORAL* requires acidity for dissolution. If concomitant antacids, anticholinergics, and Hyblockers are needed, they should be given at least two hours after NIZORAL* administration. In cases of achlorhydria, the patients should be instructed to dissolve each tablet in 4 ml aqueous solution of 0.2 N HO. For ingesting the resulting mixture, they should use a glass or plastic straw so as to avoid contact with the teeth. This administration should be followed with a cup of tap water.
Iitfornmlpn lor Patient: Patient should be instructed to report any signs and symptoms which may suggest liver dysfunction so that appropriate biochemical testing can be done. Such signs and symptoms may include unusual fatigue, nausea or vomiting, jaundice, dark urine or pale stools (see WARNINGS).
Oruf Interactions: There is no evidence for clinically significant interaction with oral anticoagulant or oral hypoglycemic agents.
CarcJnogenttis, Mutagenesis, Impairment of FertNty:
The dominant lethal mutation test in male and Ternale mice revealed that single oral doses of NIZORAL* as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames' Salmonella microsomal activator assay was also negative. Praanancy: Teratogenic effects: Pregnancy Category C. NIZORAL* has been shown to be teratogenic (synoactylia and oligodactylia) in the rat when given in trie diet at 80 mg/kg/day, (10 times the maximum recommended human dose). However, these effects may be related to maternal toxicity, evidence of which also was seen at this and higher dose levels. There are no adequate and well controlled studies in pregnant women. NIZORAL* should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic effects: NIZORAL* has also been found to be embryotoxic in the rat when given in the diet at doses higher than 80 mg/kg during the first trimester of gestation. In addition, dystocia (difficult labor) was noted in rats administered NIZORAL* during the third trimester gl gestation. This occurred when NIZORAL* was administered at doses higher than 10 mg/kg (higher than 1.25 times the maximum human dose). It is likely that both the malformations and the embryotoxicity resulting from the administration of NIZORAL* during gestation are a reflection of the particular sensitivity of the female rat to this drug. For example, the oral LDu of NIZORAL* given by gavage to the female rat is 166 mg/kg, whereas in the male rat the oral LD» is 287 mg/kg. 
